Evaluating the safety and effects of ID110521156 in healthy adults
Official title: A Randomized, Double-blinded, Placebo-controlled, Multiple Ascending Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administrations of ID110521156 in Healthy Subjects
Run by IlDong Pharmaceutical Co Ltd · NCT06635226 · Data updated 2026-11-12
This study tests how safe a new drug called ID110521156 is and how it works in healthy adults aged 19 to 50.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 19 Years to 50 Years |
| Sex | All |
| Enrollment | 36 (estimated) |
| Sponsor | IlDong Pharmaceutical Co Ltd Industry-sponsored |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | November 13, 2024 |
| Main results expected | June 19, 2025 |
| Study ends | June 19, 2025 |
| Registry record updated | December 24, 2024 |
| Trial ID | NCT06635226 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are healthy adults aged 19 to 50 years with a BMI of 27 kg/m2 or higher.
✕Probably not a fit
Patients with significant health issues or those who have recently participated in other investigational drug studies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of ID110521156 in healthy adult subjects. Participants will receive either the investigational drug or a placebo to determine how the drug behaves in the body and its potential effects. The study will involve healthy adults aged 19 to 50 years with specific body weight and health criteria. The findings will help inform future research and potential therapeutic applications of ID110521156.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the safety and effects of ID110521156, paving the way for its use in treating various conditions.
How similar studies have gone: Other studies evaluating similar pharmacological agents have shown promise, but the specific approach of this study is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy subjects aged 19 to 50 years at the time of Screening. * Body mass index (BMI) within ≥27 kg/m2; and a total body weight ≥ 50 kg * Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study * For female subjects, not pregnant or lactation women, or naturally menopausal (spontaneous amenorrhea for at least 12 months) or surgically infertility (bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy etc). Exclusion Criteria: * Evidence or history of clinically significant hepatic, renal, neurological, immunological, pulmonary, gastrointestinal (including pancreatitis), endocrine, hematological, cardiovascular, urinary, psychiatric disease, sexual dysfunction or drug allergies. * Treatment with an investigational drug (including a bioequivalence study) within 180 days prior to the scheduled date of first administration of the investigational product. * Fertile male subjects who are unwilling or unable to use a highly effective method of contraception for the duration of the study and for at least 90 days after the last dose.
Where it's running
-
Seoul National University Hospital
Seoul, South Korea Recruiting
Study contacts
- Study coordinator: Clinical Ops Study Leader
- Email: eh.hong@yunovia.com
- Phone: +82-10-4570-1405
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PSTC100 study in healthy adults (Phase 1)
A Phase 1 study in healthy adults tests PSTC100 across increasing single and multiple doses to see if it is safe and how the body handles the drug.
-
PSTB100 first-in-human test in healthy adults
This Phase 1 study tests PSTB100 tablets in healthy adults to see if they are safe, tolerable, and how the body processes the drug.
-
Hip bump manipulation compared with sham for hip rotation, strength, and landing mechanics in healthy adults
This project will try a quick high-velocity hip bump manipulation to see if it improves hip internal rotation, hip external rotator strength, and bipodal landing mechanics in healthy adults aged 18–45.
-
Bioequivalence comparison between YHP2508B and YHR2602 in healthy adults
This study tests whether YHP2508B and YHR2602 deliver similar amounts of the drug in healthy adults after a single dose.
-
Bioequivalence test of two drugs in healthy adults
This study tests whether YHP2508A and YHR2601 are bioequivalent in healthy volunteers.
-
Reactive Balance Training with Augmented Reality for Older Adults
This study tests whether reactive balance training using augmented reality helps older adults who are at risk of falling, compared with regular treadmill walking.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.